Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 3 5Phase 2 4Phase 2/3 2Phase 1/2 2

Status

Terminated 2Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5

Conditions

Ovarian Neoplasms 5Lymphoma, T-Cell, Peripheral 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Paclitaxel 79Carboplatin 64Bevacizumab 33liposomal doxorubicin 29Topotecan 28Gemcitabine 25Cisplatin 19olaparib 18Drug Therapy 12Doxorubicin 12Taxes 11niraparib 9Docetaxel 6CP protocol 6Trabectedin 5Hyperthermic Intraperitoneal Chemotherapy 5Etoposide 5Cyclophosphamide 51-dodecylpyridoxal 5rucaparib 4pembrolizumab 4avelumab 4atezolizumab 4Immunoglobulin G 4Ifosfamide 4Disulfides 4Dexamethasone 4Chemotherapy, Adjuvant 4trebananib 3fluzoparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Ovarian Neoplasms × 1-dodecylpyridoxal × Clear all
NCT07564141 2026-06-03

RAINFOLâ„¢-07

Genmab

Phase 3 Not yet recruiting
688 enrolled
Gynecologic

Ovarian Neoplasms

NCT02580058 2023-07-10

JAVELIN Ovarian 200

Pfizer

Phase 3 Completed
566 enrolled 40 charts
Gynecologic

Ovarian Neoplasms

NCT03690739 2022-02-24

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

AGO Research GmbH

Phase 3 Terminated
9 enrolled
Gynecologic

Ovarian Neoplasms

NCT01837251 2021-07-13

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

AGO Research GmbH

Phase 3 Completed
682 enrolled
Gynecologic

Ovarian Neoplasms

NCT01281254 2017-12-02

TRINOVA-2

Amgen

Phase 3 Terminated
223 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡